

LEAP-BIO

LEAP-BIO is a COSME project which aims to **develop IP licensing intermediary services** for early stage assets in **Pharma** and **BIOTech**.



PROJECT START:
SEPTEMBER 1ST, 2022

DURATION:
18 MONTHS

LEAD PARTNER:
EURASANTÉ (FRANCE)

The main goal of the project is to **leverage the extensive expertise and networks of the consortium to develop an early-stage focused IP licensing intermediary service** for biopharma SMEs and startup companies in the target regions – mainly Portugal, France, and Italy but also Spain and the Wallonian region in Belgium.



THE OBJECTIVES:

- 1. ESTABLISH** strategies and tools to facilitate the licensing of early-stage assets in the biopharma industry
- 2. IDENTIFY** early-stage assets matching the licensing interests of leading biopharma players
- 3. SUPPORT** the negotiation of licence agreements of early-stage IP assets
- 4. PROMOTE** the use of IP Licensing intermediary services – in particular via digital tools – and disseminate best practices to target audiences: Mapping and analysis of existing tools, lessons learned, and good practices
- 5. IDENTIFY AND CHARACTERISE** licensing interests from the top 50 global pharma companies, and well-financed, public listed European biotech companies
- 6. IMPROVE** the matchmaking process with the combination of digital tools and face-to-face partnering events
- 7. ESTABLISH** a sustainable IP licensing intermediary service of early-stage assets

www.lille.eurasante.com/our-european-projects/ongoing-european-projects/leap-bio/



PARTNERSHIP:



João Lobo Antunes



Consorzio Italtbiotec



Funded by
the European Union